Cargando…
Endometrial clear cell carcinoma: A population-based study
BACKGROUND: A systematic analysis of prognostic factors concerning endometrial clear cell carcinoma (ECCC) is lacking. The current study aimed to construct nomograms predicting the overall survival (OS) of ECCC patients. METHODS: We performed a retrospective study, and predicted nomograms for 3-, 5-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638001/ https://www.ncbi.nlm.nih.gov/pubmed/36353550 http://dx.doi.org/10.3389/fonc.2022.961155 |
_version_ | 1784825309109944320 |
---|---|
author | Cui, Pengfei Cong, Xiaofeng Zhang, Youhao Zhang, Huimin Liu, Ziling |
author_facet | Cui, Pengfei Cong, Xiaofeng Zhang, Youhao Zhang, Huimin Liu, Ziling |
author_sort | Cui, Pengfei |
collection | PubMed |
description | BACKGROUND: A systematic analysis of prognostic factors concerning endometrial clear cell carcinoma (ECCC) is lacking. The current study aimed to construct nomograms predicting the overall survival (OS) of ECCC patients. METHODS: We performed a retrospective study, and predicted nomograms for 3-, 5-, and 10-year OS were established. The nomograms were verified with the consistency index (C-index), calibration curve, and decision curve analysis (DCA). RESULTS: A total of 1778 ECCC patients, 991 from FIGO stage I/II and 787 from FIGO stage III/IV, were included in this study. The age at diagnosis, marital status, T stage, tumor size, and surgery-independent prognostic factors in FIGO stage I/II, and the age at diagnosis, T stage, lymph node involvement, distant metastasis, tumor size, surgery, radiotherapy, and chemotherapy in FIGO stage III/IV were independent prognostic factors. The C-indexes of the training and validation group were 0.766 and 0.697 for FIGO stage I/II and 0.721 and 0.708 for FIGO stage III/IV, respectively. The calibration curve revealed good agreement between nomogram-predicted and actual observation values. The DCA established that nomograms had better clinical benefits than the traditional FIGO stage. CONCLUSIONS: The predicted nomograms showed good accuracy, excellent discrimination ability, and clinical benefits, depicting their usage in clinical practice. |
format | Online Article Text |
id | pubmed-9638001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96380012022-11-08 Endometrial clear cell carcinoma: A population-based study Cui, Pengfei Cong, Xiaofeng Zhang, Youhao Zhang, Huimin Liu, Ziling Front Oncol Oncology BACKGROUND: A systematic analysis of prognostic factors concerning endometrial clear cell carcinoma (ECCC) is lacking. The current study aimed to construct nomograms predicting the overall survival (OS) of ECCC patients. METHODS: We performed a retrospective study, and predicted nomograms for 3-, 5-, and 10-year OS were established. The nomograms were verified with the consistency index (C-index), calibration curve, and decision curve analysis (DCA). RESULTS: A total of 1778 ECCC patients, 991 from FIGO stage I/II and 787 from FIGO stage III/IV, were included in this study. The age at diagnosis, marital status, T stage, tumor size, and surgery-independent prognostic factors in FIGO stage I/II, and the age at diagnosis, T stage, lymph node involvement, distant metastasis, tumor size, surgery, radiotherapy, and chemotherapy in FIGO stage III/IV were independent prognostic factors. The C-indexes of the training and validation group were 0.766 and 0.697 for FIGO stage I/II and 0.721 and 0.708 for FIGO stage III/IV, respectively. The calibration curve revealed good agreement between nomogram-predicted and actual observation values. The DCA established that nomograms had better clinical benefits than the traditional FIGO stage. CONCLUSIONS: The predicted nomograms showed good accuracy, excellent discrimination ability, and clinical benefits, depicting their usage in clinical practice. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638001/ /pubmed/36353550 http://dx.doi.org/10.3389/fonc.2022.961155 Text en Copyright © 2022 Cui, Cong, Zhang, Zhang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cui, Pengfei Cong, Xiaofeng Zhang, Youhao Zhang, Huimin Liu, Ziling Endometrial clear cell carcinoma: A population-based study |
title | Endometrial clear cell carcinoma: A population-based study |
title_full | Endometrial clear cell carcinoma: A population-based study |
title_fullStr | Endometrial clear cell carcinoma: A population-based study |
title_full_unstemmed | Endometrial clear cell carcinoma: A population-based study |
title_short | Endometrial clear cell carcinoma: A population-based study |
title_sort | endometrial clear cell carcinoma: a population-based study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638001/ https://www.ncbi.nlm.nih.gov/pubmed/36353550 http://dx.doi.org/10.3389/fonc.2022.961155 |
work_keys_str_mv | AT cuipengfei endometrialclearcellcarcinomaapopulationbasedstudy AT congxiaofeng endometrialclearcellcarcinomaapopulationbasedstudy AT zhangyouhao endometrialclearcellcarcinomaapopulationbasedstudy AT zhanghuimin endometrialclearcellcarcinomaapopulationbasedstudy AT liuziling endometrialclearcellcarcinomaapopulationbasedstudy |